Hyperthermic intraperitoneal chemotherapy and colorectal cancer: From physiology to surgery

Ammerata, Giorgio; Filippo, Rosalinda; Laface, Carmelo; Méméo, Riccardo; Solaini, Leonardo; Cavaliere, Davide; Navarra, Giuseppe; Ranieri, Girolamo; Currò, Giuseppe; Ammendola, Michele

doi:10.12998/wjcc.v10.i30.10852

Cited by 3 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies described the immunosuppressive role of pro-angiogenetic factors in three different ways. First, Treg cell proliferation and their homing to TME can be stimulated by VEGF [53,54]. This latter is also able to inhibit DC maturation, CD8+ T cell proliferation and action, and to promote T cell exhaustion by upregulating PD-1 expression on T cells [32,34,37,[55][56][57][58][59][60].…”

Section: Pd-1/pd-l1 Inhibitors Plus Antiangiogenetic Therapiesmentioning

confidence: 99%

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma

Laface¹,

Ranieri

Maselli³

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

One of the most important abilities of a tumor is to establish a state of immunosuppression inside the tumor microenvironment. This is made possible through numerous mechanisms of tumor immune escape that have been identified in experimental studies during the last decades. In addition, the hepatic microenvironment is commonly oriented towards a state of immune tolerance because the liver receives blood from the hepatic arteries and portal veins containing a variety of endogenous antigens. Therefore, the hepatic microenvironment establishes an autoimmune tolerance, preventing an autoimmune reaction in the liver. On this basis, hepatic tumor cells may escape the immune system, avoiding being recognized and destroyed by immune cells. Moreover, since the etiology of Hepatocellular Carcinoma (HCC) is often related to cirrhosis, and hepatitis B or C, this tumor develops in the context of chronic inflammation. Thus, the HCC microenvironment is characterized by important immune cell infiltration. Given these data and the poor prognosis of advanced HCC, different immunotherapeutic strategies have been developed and evaluated for these patients. In this review, we describe all the clinical applications of immunotherapy for advanced HCC, from the drugs that have already been approved to the ongoing clinical trials.

show abstract

Section: Pd-1/pd-l1 Inhibitors Plus Antiangiogenetic Therapiesmentioning

confidence: 99%

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma

Laface¹,

Ranieri

Maselli³

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is a need to discover treatments for tumor complications, such as obstruction and malignant ascites, remove any macroscopic cancer on the peritoneal surface, and improve median survival. Surgery in conjunction with HIPEC may be a viable therapy option, particularly for younger patients (less than 50 years old) with locally metastasized (pT4) CRC [7]. Treatment of colon cancer is very crucial for a patient's survival.…”

Section: Introductionmentioning

confidence: 99%

A Clinical Study of Intraoperative Perfusion Chemotherapy With Raltitrexed in Colon Cancer: A Prospective Cohort

Adnan,

Hussain,

Amir

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction: Colorectal cancer (CRC) ranks as the second leading cause of cancer-related mortality among women and the third leading cause of cancer-associated mortality among men. Treatment of colon cancer is very crucial for a patient's survival. In this study, we assessed the reliability, efficacy, and safety of raltitrexed in intraoperative intraperitoneal chemotherapy for colon cancer.Methodology: A total of 57 patients with clinical stages II and III of colon cancer were included in the study. R0 resection surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) procedure was done with raltitrexed. It was given in a dose of 3 mg/m 2 in a 0.9% NS injection in a volume of 500 milliliters. Postoperative complications were observed.Result: The most common postoperative complication was nausea/vomiting, which was seen in 21 out of 57 patients (37%). The second most common complication was fever (18/57). None of the patients died or developed renal toxicity, hepatic toxicity, and intestinal obstruction.Conclusion: Raltitrexed is a reliable, efficient, and safe drug and can be used in intraoperative intraperitoneal chemotherapy of colon cancer.

show abstract

Effectiveness of hyperthermic intraperitoneal chemotherapy during primary curative resection for colorectal carcinoma

Zhou,

Wang,

et al. 2024

Int J Colorectal Dis

View full text Add to dashboard Cite

Purpose Peritoneal metastasis (PM) is the life-threatening cause of colorectal cancer patients (CRC). Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery exhibited promising effects in preventing recurrence and increasing the survival of CRC patients. However, the outcomes of HIPEC on treating advanced CRC with risk of PM are still controversial. Here, we retrospectively examined the impact of HIPEC on preventing PM and its overall effects on patients with locally advanced CRC who underwent primary curative resection at our center. Methods We retrospectively analyzed 45 patients diagnosed with locally advanced colorectal cancer (CRC) who underwent primary curative laparoscopic surgery with proactive hyperthermic intraperitoneal chemotherapy (HIPEC), in conjunction with adjuvant systemic chemotherapy at our center between 2019 and 2022. An additional 55 patients with locally advanced CRC who underwent similar surgery and received adjuvant systemic chemotherapy but did not undergo HIPEC during the same period were selected as the control group. Disease-free survival (DFS), overall survival (OS), and PM incidence were compared between patients with and without HIPEC. Results and conclusions The cumulative PM incidence was 2.2% in the HIPEC group and 14.5% in the control group( P = 0.0347). No significant adverse effects were observed in the HIPEC group. Furthermore, Kaplan–Meier survival analysis showed that the HIPEC correlated to better DFS [hazard ratio (HR) 0.4670, 95% confidence interval (CI) 0.2305–0.9462; P = 0.0345] and extended the overall survival of CRC patients [hazard ratio (HR) 0.3978, 95% confidence interval (CI) 0.1684–0.9395; P = 0.0355]. Therefore, our data supports that adjuvant HIPEC can prevent peritoneal failure in CRC patients and improve both PFS and OS survival following primary curative resection.

show abstract

Hyperthermic intraperitoneal chemotherapy and colorectal cancer: From physiology to surgery

Cited by 3 publications

References 56 publications

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma

Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma

A Clinical Study of Intraoperative Perfusion Chemotherapy With Raltitrexed in Colon Cancer: A Prospective Cohort

Effectiveness of hyperthermic intraperitoneal chemotherapy during primary curative resection for colorectal carcinoma

Contact Info

Product

Resources

About